<a href="https://www.fiercebiotech.com/biotech/real-momentum-or-completely-absurd-trump-support-offers-psychedelic-field-murky-path" hreflang="en">‘Real momentum’ or ‘completely absurd’? How Trump’s support has shaken up psychedelics</a>
The Trump administration's recent push to fast-track FDA reviews for psychedelic drugs has sparked debate, with supporters highlighting the potential for innovative mental health treatments, while critics argue that political influence undermines scientific integrity in regulatory processes. Companies like Compass Pathways have received priority review vouchers for psilocybin-assisted therapies, signaling a significant shift in the federal government's stance on psychedelics as legitimate medical options.
The recent political shifts under the Trump administration have led to the FDA fast-tracking reviews of psychedelic drugs for mental health, providing strategic opportunities for biotechs like Compass Pathways, Transcend Therapeutics, and Usona Institute through the awarding of Commissioner’s National Priority Vouchers (CNPVs). This could be a pivotal moment for investors and stakeholders in the psychedelic sector, as these developments signal a significant regulatory momentum that may expedite the path to market for psychedelic therapies, despite concerns about political influence.